Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
Following approval from the European Commission, PFE's Hympavzi becomes the first hemophilia medicine in the European Union ...
Armed robbery in Revesby21h
FDA Greenlights Pfizer's HYMPAVZI for Hemophilia A/B
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine ...
GlobalData on MSN6d
EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia
HYMPAVZI is the first anti-TFPI approved in the EU for this indication and the first therapy to be administered through a pre ...
PMLiVE4d
Pfizer’s Hympavzi receives EC approval to treat haemophilia A and B patients
Pfizer’s Hympavzi (marstacimab) has been approved by the European Commission (EC) to treat haemophilia A or B in adult and ...
The Pharma Letter6d
EC approval for Pfizer’s Hympavzi
The European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab), from US pharma giant Pfizer. The ...
Daily6d
Pfizer's HYMPAVZI gets European Commission Approval to Treat Severe Hemophilia A and B
Delhi: Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab) ...
Pfizer announces EC approval for Hympavzi
Pfizer (PFE) announced that the European Commission, or EC, has granted marketing authorization for Hympavzi for the routine prophylaxis of ...
Armed robbery in Revesby6d
EU Greenlights Pfizer's HYMPAVZI for Severe Hemophilia
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI™ (marstacimab) for the ...
Nasdaq5d
Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization for Hympavzi (marstacimab) to treat certain hemophilia patients. With this nod, the once-weekly ...
Pfizer Gets European Approval of Hympavzi Hemophilia Drug
Pfizer said the green light makes Hympavzi the first once-weekly subcutaneous treatment in the European Union for people with severe hemophilia B and the first to be administered via a pre-filled pen ...
Yahoo6d
EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia
HYMPAVZI is a once-weekly subcutaneous treatment option for individuals with severe haemophilia A or B. Credit: Andrey_Popov/Shutterstock. The European Commission (EC ...